Determinants and Clinical Outcomes of Extended Dual Antiplatelet Therapy over 3 Years after Drug-Eluting Stent Implantation: A Retrospective Analysis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Although current guidelines recommend the administration of dual antiplatelet therapy (DAPT) for up to 12 months after the implantation of a drug-eluting stent (DES), extended DAPT is frequently used in real-world practice. Materials and Methods: From the Korean Multicenter Angioplasty Team registry, we identified a total of 1414 patients who used DAPT for >3 years after DES implantation (extended-DAPT group) and conducted a landmark analysis at 36 months after the index procedure. We evaluated the determinants for and long-term outcomes of extended DAPT and compared the occurrence of major adverse cardiovascular and cerebrovascular events (MACCE), defined as the composite of all-cause death, myocardial infarction, stent thrombosis, and stroke, between the extended-DAPT group and the guideline-DAPT group [DAPT <1 year after DES implantation (n=1273)]. Results: Multivariate analysis indicated the occurrence of acute coronary syndrome as the most significant clinical determinant of the use of extended DAPT. Bifurcation, stent diameter ≤3.0 mm, total stented length ≥28 mm, and use of first-generation DESs were also significant angiographic and procedural determinants. MACCE rates were similar between the extended-DAPT group and the guideline-DAPT group in crude analysis [hazard ratio (HR), 1.08; 95% confidence interval (CI), 0.69–1.68; p=0.739] and after propensity matching (HR, 1.22; 95% CI, 0.72–2.07; p=0.453). Major bleeding rates were comparable between the two groups. Conclusion: In patients undergoing percutaneous coronary intervention, indefinite use of DAPT does not show superior outcomes to those of guideline-DAPT. Major bleeding rates are also similar.
Abstract
Purpose: Although current guidelines recommend the administration of dual antiplatelet therapy (DAPT) for up to 12 months after the implantation of a drug-eluting stent (DES), extended DAPT is frequently used in real-world practice. Materials and Methods: From the Korean Multicenter Angioplasty Team registry, we identified a total of 1414 patients who used DAPT for >3 years after DES implantation (extended-DAPT group) and conducted a landmark analysis at 36 months after the index procedure. We evaluated the determinants for and long-term outcomes of extended DAPT and compared the occurrence of major adverse cardiovascular and cerebrovascular events (MACCE), defined as the composite of all-cause death, myocardial infarction, stent thrombosis, and stroke, between the extended-DAPT group and the guideline-DAPT group [DAPT <1 year after DES implantation (n=1273)]. Results: Multivariate analysis indicated the occurrence of acute coronary syndrome as the most significant clinical determinant of the use of extended DAPT. Bifurcation, stent diameter ≤3.0 mm, total stented length ≥28 mm, and use of first-generation DESs were also significant angiographic and procedural determinants. MACCE rates were similar between the extended-DAPT group and the guideline-DAPT group in crude analysis [hazard ratio (HR), 1.08; 95% confidence interval (CI), 0.69–1.68; p=0.739] and after propensity matching (HR, 1.22; 95% CI, 0.72–2.07; p=0.453). Major bleeding rates were comparable between the two groups. Conclusion: In patients undergoing percutaneous coronary intervention, indefinite use of DAPT does not show superior outcomes to those of guideline-DAPT. Major bleeding rates are also similar.
참고문헌 (25)
- Gargiulo G, "State of the art : duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation-past, present and future perspectives", EuroIntervention, 13, pp.717~733 (2017)
- Levine GN, "2016 ACC", AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease : A Report of the American College of Cardiology, AHA, pp.SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF, AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC[DOI]
- Mauri L, "Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents", N Engl J Med, 371, pp.2155~2166 (2014)
- Kim JS, "Comparison of sirolimus-eluting stent and paclitaxel-eluting stent for longterm cardiac adverse events in diabetic patients : the Korean Multicenter Angioplasty Team(KOMATE)registry", Catheter Cardiovasc Interv, 72, pp.601~607 (2008)
- Cutlip DE, "Clinical end points in coronary stent trials : a case for standardized definitions", Circulation, 115, pp.2344~2351 (2007)
- Thygesen K, "Third universal definition of myocardial infarction", Circulation, 126, pp.2020~2035 (2012)
- Sacco RL, "An updated definition of stroke for the 21st century : a statement for healthcare professionals from the American Heart Association", American Stroke Association, 2013, pp.44, 2064~2089
- Hicks KA, "Bleeding academic research consortium consensus report : the food and drug administration perspective", Circulation, 123, pp.2664~2665 (2011)
- Ponikowski P, "2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure : the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology(ESC). Developed with the special contribution of the heart failure association(HFA)of the ESC", Eur J Heart Fail, 18, pp.891~975 (2016)
- Thomas M, "Percutaneous coronary intervention for bifurcation disease. A consensus view from the first meeting of the European Bifurcation Club", EuroIntervention, 2, pp.149~153 (2006)
- Yeh RW, "Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention", JAMA, 315, pp.1735~1749 (2016)
- Kim BK, "A new strategy for discontinuation of dual antiplatelet therapy : the RESET Trial(REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)", J Am Coll Cardiol, 60, pp.1340~1348 (2012)
- Collet JP, "Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation(ARCTIC-Interruption) : a randomised trial", Lancet, 384, pp.1577~1585 (2014)
- Palmerini T, "Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation : a pairwise and Bayesian network meta-analysis of randomised trials", Lancet, 385, pp.2371~2382 (2015)
- Mehran R, "Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention(PARIS) : 2 year results from a prospective observational study", Lancet, 382, pp.1714~1722 (2013)
- Baber U, "Coronary thrombosis and major bleeding after PCI with drugeluting stents : risk scores from PARIS", J Am Coll Cardiol, 67, pp.2224~2234 (2016)
- Costa F, "Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy(PRECISE-DAPT)score : a pooled analysis of individual-patient datasets from clinical trials", Lancet, 389, pp.1025~1034 (2017)
- Yeh RW, "Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction", J Am Coll Cardiol, 65, pp.2211~2221 (2015)
- Cutlip DE, "Stent thrombosis in the modern era : a pooled analysis of multicenter coronary stent clinical trials", Circulation, 103, pp.1967~1971 (2001)
- Cook S, "Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation", Circulation, 115, pp.2426~2434 (2007)
- Jang WJ, "Benefit of prolonged dual antiplatelet therapy after implantation of drug-eluting stent for coronary bifurcation lesions : results from the coronary bifurcation stenting registry II", Circ Cardiovasc Interv, 11, pp.e005849~ (2018)
- Daemen J, "Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice : data from a large two-institutional cohort study", Lancet, 369, pp.667~678 (2007)
- Lagerqvist B, "Stent thrombosis in Sweden : a report from the Swedish Coronary Angiography and Angioplasty Registry", Circ Cardiovasc Interv, 2, pp.401~408 (2009)
- Collet JP, "Clinical outcome of first-vs second-generation DES according to DAPT duration : results of ARCTIC-generation", Clin Cardiol, 39, pp.192~200 (2016)
- Valgimigli M, "Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting : a randomized multicenter trial", Circulation, 125, pp.2015~2026 (2012)